Showing 6911-6920 of 7733 results for "".
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil
- Mandy Moore, Garnier Team Up for Beauty Product Recyclinghttps://practicaldermatology.com/news/mandy-moore-garnier-team-up-for-beauty-product-recycling/2457854/Nearly half of Americans don’t recycle their beauty and personal care products, which is why they account for a significant amount of landfill waste, and This Is Us star Mandy Moore, #GarnierGirl and brand ambassador, is teaming up with Garnier and DoSomething.org to kick off the seco
- Skin of Color Seminar Series to Provide Latest Research and Practical Pearls for Dermatologic Treatment of Skin of Colorhttps://practicaldermatology.com/news/skin-of-color-seminar-series-to-provide-latest-evidence-based-research-and-practical-pearls-for-dermatologic-treatment-of-skin-of-color/2457859/Now in its tenth year, the Skin of Color Seminar Series (SOCSS) will be the largest medical education event of 2018 dedicated to providing dermatologists with evidence-based research and practical pearls in treating skin of color, including patients with multiracial backgrounds. SOCSS, which will
- DermTech Receives State of New York Laboratory Permithttps://practicaldermatology.com/news/dermtech-receives-state-of-new-york-laboratory-permit/2457864/DermTech, Inc., which specializes in non-invasive molecular dermatology, has received permitting from the State of New York, Department of Public Health. The addition of a New York permit to DermTech’s current accreditations, allows it to now provide laboratory services across the
- Thermi and Sinclair Terminate Collaboration on Silhouette Instalifthttps://practicaldermatology.com/news/thermi-and-sinclair-terminate-collaboration-on-silhouette-instalift/2457866/Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift. Both companies have been working through a join
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Merkel Cell Carcinoma Is On The Risehttps://practicaldermatology.com/news/merkel-cell-carcinoma-is-on-the-rise/2457879/Merkel cell carcinoma (MCC) is on the rise, according to new research published in the Journal of the American Academy of Dermatology and presented at the American Academy of Dermatology 2018 Annual Meetin
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell
- FDA Grants Priority Review for Genentech's Rituxan for Pemphigus Vulgarishttps://practicaldermatology.com/news/fda-grants-priority-review-for-genentechs-rituxan-for-pemphigus-vulgaris/2457883/The FDA has accepted Genentech’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). Genentech is a member of the Roche Group. <